About myriad genetics inc. - MYGN
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
MYGN At a Glance
Myriad Genetics, Inc.
322 North 2200 West
Salt Lake City, Utah 84116
| Phone | 1-801-584-3600 | Revenue | 824.50M | |
| Industry | Medical Specialties | Net Income | -365,900,000.00 | |
| Sector | Health Technology | Employees | 2,700 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MYGN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.691 |
| Price to Book Ratio | 1.563 |
| Price to Cash Flow Ratio | 316.38 |
| Enterprise Value to EBITDA | -46.301 |
| Enterprise Value to Sales | 0.764 |
| Total Debt to Enterprise Value | 0.333 |
MYGN Efficiency
| Revenue/Employee | 305,370.37 |
| Income Per Employee | -135,518.519 |
| Receivables Turnover | 7.151 |
| Total Asset Turnover | 0.951 |
MYGN Liquidity
| Current Ratio | 2.486 |
| Quick Ratio | 2.257 |
| Cash Ratio | 1.118 |
MYGN Profitability
| Gross Margin | 69.933 |
| Operating Margin | -8.223 |
| Pretax Margin | -47.92 |
| Net Margin | -44.378 |
| Return on Assets | -42.198 |
| Return on Equity | -68.45 |
| Return on Total Capital | -63.326 |
| Return on Invested Capital | -52.29 |
MYGN Capital Structure
| Total Debt to Total Equity | 57.011 |
| Total Debt to Total Capital | 36.31 |
| Total Debt to Total Assets | 29.691 |
| Long-Term Debt to Equity | 55.136 |
| Long-Term Debt to Total Capital | 35.116 |